• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI’s CT agent shows promise

Article

A liver-specific CT contrast agent under development at Molecular Biosystems (MBI) was featured at the biannual Contrast Media Research Conference, held Sept. 13 through 17 in Woodstock, VT. Animal studies have shown that the agent, MB-840, could help

A liver-specific CT contrast agent under development at Molecular Biosystems (MBI) was featured at the biannual Contrast Media Research Conference, held Sept. 13 through 17 in Woodstock, VT. Animal studies have shown that the agent, MB-840, could help clinicians identify and monitor primary and metastatic liver tumors as small as 1 to 2 mm, whereas water-soluble CT contrast agents can detect tumors no smaller than 20 mm. MB-840 could also help physicians find diseases of the hepatobiliary system, MBI said. The San Diego, CA, company expects to begin clinical trials for the agent next year, according to Dr. Howard Dittrich, executive vice president. MBI also developed Optison, an ultrasound contrast agent cleared by the FDA in 1997 (SCAN 1/14/98).

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.